In the News January 31, 2019

The Deal | Alexion, Caelum Collaborate

Alston & Bird is noted for representing Fortress Biotech, Inc., and Caelum Biosciences Inc. in a deal with Alexion Pharmaceuticals Inc. to develop a treatment for a rare systemic disorder.
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222
This website uses cookies to improve functionality and performance. By continuing to browse this site, you are consenting to the use of cookies on this website. For details, see our Privacy Statement